Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer (CROSBI ID 283406)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Bursać, Slađana ; Prodan, Ylenia ; Bartek, Jiri ; Volarević, Siniša
engleski
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
Ribosome biogenesis (RiBi) is one of the most complex and energy demanding processes in human cells, critical for cell growth and proliferation. Strong causal links between inherited and acquired impairment in RiBi with cancer pathogenesis are emerging, pointing to RiBi as an attractive therapeutic target for cancer. Here, we will highlight new knowledge about causes of excessive or impaired RiBi and the impact of these changes on protein synthesis. We will also discuss how new knowledge about secondary consequences of dysregulated RiBi and protein synthesis, including proteotoxic stress, metabolic alterations, adaptive transcriptional and translational programs, and the impaired ribosome biogenesis checkpoint (IRBC) provide a foundation for the development of new anticancer therapies.
dysregulated RiBi in cancer ; IRBC ; p53 ; RiBi inhibitors in cancer therapy
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Biologija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje), Temeljne medicinske znanosti